IP Verse

Novartis competitive analysis

Latest oppositions filed by Novartis

Explore patent oppositions filed by Novartis against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP2784084
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECHJul 24, 2019
EP2888626
Contact Lens With A Hydrophilic LayerOCULAR DYNAMICSJan 18, 2019
EP2794727
Ionic Silicone HydrogelsJOHNSON & JOHNSON VISION CAREOct 24, 2018
EP2705073
Macroinitiator Containing Hydrophobic SegmentJOHNSON & JOHNSON VISION CAREOct 10, 2018
EP2855545
Polymers And Nanogel Materials And Methods For Making And Using The SameJOHNSON & JOHNSON VISION CAREAug 1, 2018
EP1623269
Hydrogel Contact Lenses And Package Systems And Production Methods For SameCOOPERVISIONFeb 9, 2018
EP2936216
Ophthalmic Devices For Delivery Of Beneficial AgentsCOOPERVISIONJun 6, 2017
EP2710355
Method Of Detecting Polymorphs Using Synchrotron RadiationZACH SYSTEMApr 27, 2017
EP2705390
Medical Devices Having Homogeneous Charge Density And Methods For Making SameJOHNSON & JOHNSON VISION CAREApr 18, 2017
EP2855546
Contact Lenses Comprising Water Soluble N-(2 Hydroxyalkyl) (Meth)Acrylamide Polymers Or CopolymersJOHNSON & JOHNSON VISION CAREApr 7, 2017

Latest patents of Novartis opposed by its competitors

Explore Novartis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP2235159
Aug 12, 2026Fermentation Processes For Cultivating Streptococci And Purification Processes For Obtaining Cps Therefrom1
EP4397376
Nov 26, 2025Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor1
EP4197530
Nov 12, 2025Ribociclib Tablet3
EP3679922
Oct 8, 2025Syringe4
EP3676404
Sep 3, 2025Methods Of Selecting A Treatment For Cancer Patients2
EP2124547
Jun 18, 2025Cancer Treatment Method1
EP3411021
May 14, 2025New Use Of A Combination Of Sacubitril And Valsartan8
EP4212152
Apr 30, 2025Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure14
EP4218732
Mar 26, 2025Tablets Comprising Eltrombopag Olamine3
EP3143995
Jan 15, 2025A Rapamycin Derivative For Treating Lung Cancer7

Latest PTAB cases involving Novartis

Discover the latest PTAB cases involving Novartis, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 30, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Novartis

IPR2023-01346Aug 28, 2023NOVARTIS PHARMACEUTICALSTHE REGENTS OF THE UNIVERSITY OF MICHIGANFinal Written Decision - Appealed
IPR2023-01347Aug 28, 2023NOVARTIS PHARMACEUTICALSTHE REGENTS OF THE UNIVERSITY OF MICHIGANTerminated-Adverse Judgment
IPR2023-01044Jun 30, 2023NOVARTIS GENE THERAPIESGENZYMETerminated-Settled
IPR2023-01045Jun 30, 2023NOVARTIS GENE THERAPIESAVENTISTerminated-Settled
IPR2023-00608Feb 22, 2023NOVARTIS GENE THERAPIESGENZYMEInstitution Denied
IPR2023-00609Feb 22, 2023NOVARTIS GENE THERAPIESGENZYMEInstitution Denied
IPR2022-00886Apr 20, 2022NOVARTIS PHARMACEUTICALSSHILPA PHARMAFinal Written Decision
IPR2022-00853Apr 12, 2022MILTENYI BIOMEDICINENOVARTIS PHARMAInstitution Denied
IPR2021-00816Apr 16, 2021REGENERON PHARMACEUTICALSNOVARTIS PHARMAFinal Written Decision
IPR2020-01263Aug 7, 2020BIOCON PHARMANOVARTIS PHARMACEUTICALSInstitution Denied

Peer Comparison New

IP litigation analysis comparing Novartis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
NOVARTIS12564 - 21
GENERICS UK319 - - -
STADA ARZNEIMITTEL15332 - -
TEVA PHARMACEUTICAL INDUSTRIES LTD2727 - -